Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radiotherapy, Chemotherapy and Anti-PD-1 Immunotherapy Followed by Surgical Resection in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Single Arm, Phase II Trial

NCT06121700 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06121700
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06121700 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radiotherapy, Chemotherapy and Anti-PD-1 Immunotherapy Followed by Surgical Resection in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma: A Prospective, Single Arm, Phase II Trial
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
January 1, 2023
Completion date
December 31, 2027
Enrollment
55 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, adenocarcinoma of the stomach, gastroesophageal junction adenocarcinoma, gastroesophageal-junction cancer, metastatic adenocarcinoma, metastatic cancer, metastatic gastric cancer, oligometastatic disease, stomach neoplasm